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Abstract 
Background: Ghana has made impressive progress against malaria, decreasing mortality and morbidity by over 
50% between 2005 and 2015. These gains have been facilitated in part, due to increased financial commitment from 
government and donors. Total resources for malaria increased from less than USD 25 million in 2006 to over USD 100 
million in 2011. However, the country still faces a high burden of disease and is at risk of declining external financing 
due to its strong economic growth and the consequential donor requirements for increased government contribu-
tions. The resulting financial gap will need to be met domestically. The purpose of this study was to provide economic 
evidence of the potential risks of withdrawing financing to shape an advocacy strategy for resource mobilization.
Methods: A compartmental transmission model was developed to estimate the impact of a range of malaria 
interventions on the transmission of Plasmodium falciparum malaria between 2018 and 2030. The model projected 
scenarios of common interventions that allowed the attainment of elimination and those that predicted transmission 
if interventions were withheld. The outputs of this model were used to generate costs and economic benefits of each 
option.
Results: Elimination was predicted using the package of interventions outlined in the national strategy, particularly 
increased net usage and improved case management. Malaria elimination in Ghana is predicted to cost USD 961 
million between 2020 and 2029. Compared to the baseline, elimination is estimated to prevent 85.5 million cases, 
save 4468 lives, and avert USD 2.2 billion in health system expenditures. The economic gain was estimated at USD 32 
billion in reduced health system expenditure, increased household prosperity and productivity gains. Through malaria 
elimination, Ghana can expect to see a 32-fold return on their investment. Reducing interventions, predicted an addi-
tional 38.2 clinical cases, 2500 deaths and additional economic losses of USD 14.1 billion.
Conclusions: Malaria elimination provides robust epidemiological and economic benefits, however, sustained 
financing is need to accelerate the gains in Ghana. Although government financing has increased in the past dec-
ade, the amount is less than 25% of the total malaria financing. The evidence generated by this study can be used to 
develop a robust domestic strategy to overcome the financial barriers to achieving malaria elimination in Ghana.
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Background
Ghana has made impressive progress in its fight against 
malaria. Malaria cases and deaths have decreased 
by over 50% and 65%, respectively, between 2005 
and 2015 [1]. Nevertheless, malaria remains a major 
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public health burden in Ghana accounting for 30% of 
outpatient attendances and 23% inpatient admissions. 
Malaria is endemic and perennial in all parts of Ghana 
with seasonal variations more pronounced in the 
north. Plasmodium falciparum accounts for over 95% 
of malaria infections. The entire population is at risk 
of malaria infection however, transmission is markedly 
less intense in large urban centers compared to rural 
areas [2].
The current strategy is based on the National Malaria 
Control Strategic Plan (NSP) for 2014–2020, which was 
finalized in August 2014 by the National Malaria Con-
trol Programme (NMCP) [3]. The scope of the strategic 
plan was to consolidate the gains and accelerate malaria 
control in the high transmission areas to further reduce 
malaria burden and move towards establishing lower-
transmission areas in Ghana by the end of 2020. The plan 
calls for reducing the malaria morbidity and mortality 
burden by 75% by the year 2020 compared to 2012.
The gains experienced in the past decade can be attrib-
uted in part due to the increased financing available to 
scale up effective interventions. In 2016, 73% of house-
holds owned at least one insecticide-treated net (ITN) 
with 52% of children having slept under a net the previ-
ous night. 78% of pregnant women received two or more 
doses of intermittent preventive treatment for preg-
nancy (IPTp) during their last pregnancy, the highest 
rate in sub-Saharan Africa. In light of the inter-regional 
and urban/rural difference in malaria burden, efforts are 
being made to adapt interventions based on the respec-
tive needs of different localities [4].
Since 2003, Ghana has benefited from a succession 
of grants from Global Fund for AIDS, Tuberculosis and 
Malaria (Global Fund) [5] with disbursements of USD 
408 million. The country currently has two active grants 
totaling USD 109 million (2018–2020). Several other 
external donors have provided financial support to the 
malaria programme including the United States Presi-
dents Malaria Initiative (PMI, the U.K. Department for 
International Development (DFID), the United Nations 
Children’s Fund (UNICEF), the World Bank, and the gov-
ernments of Japan, China, and Cuba [1]. Nevertheless, 
the country still faces a financing gap estimated at 187 
million for 2019–2020 by the Ghana National Strategic 
Plan for malaria (NSP) [3].
Government contributions made up 38% of the total 
financing for malaria in 2018 [5]. Curative services for 
malaria are covered by the National Health Insurance 
Scheme (NHIS) benefit package which is financed by a 
mix of funding from earmarked taxes and premiums paid 
by members. However, collection rates are a challenge 
and, therefore, revenue received from capitation does not 
offset any significant portion of the expenditure.
The current level of financial support the country 
receives from external partners is unlikely to be sus-
tained in the longer term. Between 2002 and 2016, Ghana 
experienced a five-fold increase in GDP per capita from 
USD 309 to USD 1517 [6–8]. As Ghana’s economy tran-
sitions towards middle income, external donor financ-
ing for health is expected to decline, with domestic or 
other sources of financing having to fill the resulting 
gap. However, experience with other countries points 
to a significant time-lag between rising national income 
and increased government health expenditure unless 
accompanied by effective advocacy backed by evidence 
outlining the risks associated with funding withdrawal. 
Historical evidence demonstrates that almost all resur-
gence events could be attributed, at least in part, to the 
weakening of malaria control programmes for a variety 
of reasons, of which resource constraints were the most 
common [9].
The aim of this analysis was, therefore, to quantify the 
epidemiological and economic impact of both a fully-
funded malaria response that will achieve malaria elimi-
nation and that of a partially-funded response that may 
potentially lead to disease resurgence. The findings of 
this work can be used to shape the advocacy strategy for 
mobilizing increased domestic resources for malaria.
Methods
This investment case projected the financial require-
ments of the malaria programme to reach malaria elimi-
nation by 2030 and values the economic and financial 
returns of reducing malaria transmission compared to 
alternative scenarios. To accomplish this, the invest-
ment case leveraged multiple methodologies and data 
sources. The study design incorporated a variety of quan-
titative methods: numerical and regression techniques to 
develop a transmission model to predict the epidemio-
logical impact of various interventions used for malaria 
control and elimination and economic analysis to esti-
mate the cost and economic impact of the interventions 
nationally and regionally. The economic analysis was 
informed by the outputs of a transmission model. All 
monetary figures are expressed in 2018 constant US dol-
lars (USD) [10].
Epidemiological model framework
A spatially explicit, compartmental, nonlinear, ordinary 
differential equation model is an extension of previ-
ously published models and have been implemented 
in R and C++ [11, 12]. The model simulated a range 
of malaria interventions and estimated their impact on 
the transmission of P. falciparum malaria between 2018 
and 2030 nationally and in the three ecological zones 
in Ghana (Coastal, Forest and Savanna). Historical data 
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from 2012 to 2018 was used to parameterize and fit the 
model. The key transmission features and drivers of 
transmission in the model included:
• Infection classes dependent on the level of severity 
of infection.
• Development and loss of immunity against clinical 
infection.
• Superinfection.
• Subnational climatic variation (seasonality).
• Importation of infection.
More details on the model have been published else-
where [11–13].
Interventions modelled included:
• Passive Case detection (routine diagnosis and treat-
ment in health facilities and the community).
• Vector Control:
– Distribution of LLINs.
– Distribution of LLINsIRS.
• Healh System Strengthening (supportive super-
vision, training for improved malaria testing and 
treatment and supply chain management support).
• Social and behavioural change (SBC) for improved 
health-seeking behaviour.
• Seasonal malaria chemoprevention (SMC).
• Intermittent preventive treatment (IPTp).
Data sources used were:
• Data from the NMCP (monthly incidence and 
deaths by district from the Health Management 
Information System (HMIS)).
• WHO World Malaria Reports and Annexes.
• Peer reviewed literature.
• Expert opinion (for assumptions where data were 
unavailable).
Four scenarios and two reverse scenarios were devel-
oped in collaboration with the NMCP:
• Baseline scenario existing set of malaria control 
activities as implemented in 2018 with intervention 
coverage levels of 2018.
• Fully funded response (FFR) this scenario modelled 
the impact of a fully funded scenario with the tar-
gets as outlined in the NSP. It must be noted that 
the current NSP was developed as a “malaria con-
trol” strategy rather than an “elimination” strategy.
• Better use of nets added to the “fully funded response” 
through the use of SBC (social and behavioural 
change) to increase the usage of LLINs. Given the 
low usage of nets in Ghana, interventions to increase 
usage beyond the estimated 41.7% recorded in 2016 
[14–16] were added to simulate increased net use. 
The interventions modelled were a combination of 
activities of a “hang-up campaign” as well as SBC and 
IEC and based on a 2014 study in Ghana [17], where 
LLIN use by children under five years increased to 
77.4% in households where some or all LLINs were 
hung by a campaign volunteer accompanied by SBC/
IEC activities in the community, compared to 53.9% 
in households without these interventions. These 
interventions increased the odds of a child sleep-
ing under an LLIN approximately 1.5 times when 
adjusted for other factors that may explain variation 
in use (adjusted OR: 1.57; 95% CI 1.09, 2.27; p = 0.02). 
These odds when applied to 41.7% reported usage 
with 40% protection given usage (a meta-analysis of 
protective efficacy from use predicted that LLINs had 
a protective efficacy of 39.8% (IQR 20.2–50.3%) and 
28.5%, (IQR 8.8–47.3%) for IRS. Thus for LLINs there 
is a median effective protection of 16.6%)) result in a 
median protective efficacy of 24.9% [18].
• Increase treatment-seeking from 73 to 90% (through 
SBC) was added to the “better use of nets” scenario.
• Reverse scenarios Reduce the amount of funding for 
the implementation of activities from the 2018 base-
line coverage. Where:
– Reverse 1: cutting out IRS, SMC and LLINs by 50%.
– Reverse 2: cutting out IRS, SMC (LLINs remain at 
2018 levels).
The scenarios were developed in collaboration with the 
NMCP. Table 1 describes the scenarios in detail.
Economic analysis
Using a societal perspective and cost of illness approach 
[19], the economic burden of malaria in 2018 was evalu-
ated. Specifically, (i) direct health system costs, (ii) direct 
household costs, and (iii) indirect costs were estimated. 
Table 2 illustrates the framework used.
Direct health system costs
To facilitate the gathering of direct cost data, an inter-
view guide and data entry sheet were developed to collect 
existing costing data, identify gaps, and locate additional 
data to fill gaps. These interviews were conducted in a 
semi-structured format with key malaria programme 
personnel who were familiar with programme spending 
patterns and records. Data on government and external 
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spending were collated. National health system costs out-
side of vertical malaria programme expenditures were 
included as much as possible to obtain the total actual 
cost to the health system in Ghana. When expendi-
tures were unavailable, budget figures, National Health 
Accounts (NHA) and secondary sources such as peer-
reviewed or grey literature or deduction were used. Costs 
of treating outpatient and inpatient malaria cases were 
obtained from the NHA [20, 21].
Individual costs were extracted and aggregated to 
obtain estimates of the costs of each intervention. The 
cost of each scenario was estimated using a cost estima-
tion model fed by outputs of the transmission model. The 
cost of each scenario was then used to obtain the incre-
mental or additional cost of a fully funded response com-
pared to the baseline. All costs were discounted at 7%. 
The discount rate used was based on the inflation rate 
and the expert opinion of economists in-country. Addi-
tional file 1: Table S1 contains the cost inputs used in the 
analysis.
Direct household costs
Malaria exacts a significant financial burden on house-
holds. Malaria patients often pay for transportation 
to access health facilities, diagnostic services, and 
medicines. In Ghana, although testing and treatment 
Table 1 Scenarios modelled
a LLIN coverage determined by LLIN usage and effectiveness at reducing transmission
No. Name Description Assumptions
1. Baseline Existing set of malaria control activities in 2018
Passive testing and treating of positive malaria cases 
(community and facility-based)
Distribution of LLINs with  coveragea and usage levels 
maintained at 2018 levels
IRS coverage continued at 2018 levels (6%)
Seasonal malaria chemoprophylaxis continued at 2018 
levels
IPTp continued at 2018 levels (~ 47%)
Maintain proportions of participants who receive 1, 2, 3, 
4, 5 doses
Distribute routine LLINs to participants of IPTp
No cost and service difference between community and 
facility-based treatment avenues
Mass distribution of LLINs every 3 years, in line with data 
(Coverage 2016-2018: 32%, 9%, 100%)
Proportion of participants who take 1,2,3, 4, 5 doses of 
IPTp remains constant
2. Fully-funded response (FFR) Baseline +
Test 100% of all suspected cases and treat 100% of 
positive cases
IRS coverage > 80% (to cover Upper East, Upper West, 
Northern and Brong Ahafo Region (78% of population 
of the Savanna zone))
Increase IPTp3 to 80%
SMC extended to Northern in 2019
Supportive supervision and training to enable better 
testing and treating (applied annually per PAR)
IRS is an annual cost
IPTp costs for dosage only (through existing ANC)
3. Better use of nets Fully-funded response +
SBC (social and behavioural change) to increase the 
usage of LLINs
Distribution of LLINs every 3 years, en masse
SBC costs applied to cover 1/3 of the country per year, 
allowing for full coverage with every mass distribution
Costs applied annually at 1/3 coverage per par
Impact of SBC: Increase in net use by 50%
4. Health System Acceleration Better use of nets +
Increase treatment-seeking from 73% to 90% (through 
increasing SBC)
Increased SBC costs to increase treatment-seeking
Costs applied annually per par
5. Reverse Cut IRS
Cut SMC
Cut nets by 50%
6. Reverse 2 Cut IRS
Cut SMC
Table 2 Framework for estimating the economic burden of malaria in Ghana
Direct health system costs Direct household costs Indirect costs
National and subnational expenditures on malaria 
interventions
Out-of-pocket expenditures for treatment-
seeking
Productivity losses among malaria patients and 
caregivers
Value of life years lost due to premature death
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for malaria are free, prepaid or covered by the NHIS, 
malaria patients still incur out-of-pocket expenditures 
(OOP) for transport, food and other expenses not 
covered through the public sector. To estimate direct 
household costs on malaria, the number of reported 
OP and IP malaria cases in 2018 was multiplied by the 
mean OOP spending (separately for OP and IP cases). 
Data on OOP was obtained from published literature 
[22, 23].
Indirect costs
The economic impact of malaria extends beyond the 
health system. Patients forego income while recovering 
from malaria, and caregivers looking after ill children 
and the elderly also lose out on potential earnings. Soci-
ety also incurs an indirect cost due to premature deaths 
through losses in lifetime productivity and in the social 
value people place in living longer, healthier lives.
To evaluate the economic impact of malaria-related 
morbidity, the foregone income of malaria patients and 
caregivers was calculated. The gross domestic product 
(GDP) per capita per day was obtained from 2018 GDP 
estimates from World Bank Data [7]. The resulting fig-
ure was used as a proxy for the average income per capita 
and multiplied by the duration of OP and IP illness from 
published literature and the number of reported OP and 
IP cases. In addition, the effect of reduced productivity 
from “presenteeism” was calculating by assuming that 
adults retuning to work would be 50% less productive for 
an additional 6 days. This assumption was made based on 
interviews in Ghana.
A full income accounting approach was used to quan-
tify the economic impact of premature death as pos-
tulated by the Lancet Commission on health [24]. 
Assuming 40 years as the average age of malaria-related 
adult deaths and 2.5 years as the average death amongst 
children under 5 years, the average remaining life expec-
tancy of males and females was multiplied by the value 
of each additional life year (VLY). Life expectancy was 
retrieved from the Central Statistics Service [18]. One 
VLY was assumed to be 4.2 times the 2018 GDP per cap-
ita of Ghana [24].
Cost savings from reduced public and private expen-
ditures on malaria are likely to spur consumer spending 
and create new businesses thus injecting more money 
into the local economy. Throughout the process, overall 
disposable incomes increase, creating more markets for 
local businesses. These induced responses result in an 
economic multiplier or “ripple” effect. A 2011 USAID 
report [25] estimated that income multipliers in West 
Africa lay between 1.58 and 2.43. An average multiplier 
of 2 was, therefore, used for the purposes of this analysis.
Economic benefits estimation
To estimate the benefits of elimination, the averted costs, 
cases and deaths were calculated. The mortality and mor-
bidity averted from malaria elimination were obtained 
by subtracting the estimated cases and deaths in the 
fully funded scenarios from the corresponding outputs 
of the “business as usual” scenario. Similarly, the excess 
cases and deaths in the reverse scenarios were calculated 
by subtracting from the corresponding outputs of the 
“business as usual” scenario. These health benefits were 
calculated using the methodology and inputs previously 
outlined.
Direct costs averted to the health system includes costs 
associated with diagnosis and treatment costs of IPs and 
OPs;
• Direct cost averted to the individual households is 
out-of-pocket (OOP) expenditures for seeking care; 
and.
• Indirect cost averted to the society due to patients’ 
lost productivity due to premature death and mor-
bidity and caregivers reduced economic output.
The benefits of investing and not investing in malaria 
control and elimination were estimated as the sum of the 
direct cost savings to the health system from reduced use 
of outpatient and inpatient health services and reduction 
in cost of delivering malaria control activities; the direct 
cost savings to households; and the indirect cost savings 
of reduced morbidity and mortality from malaria calcu-
lated above.
The Net Present Value (NPV) was calculated to obtain 
the present value of the future revenue generated from 
elimination using standard economic techniques. The 
purpose was to give a true picture of the financial value 
of an investment made today whereby savings would be 
accrued in the future [19]. The timeframe used for calcu-
lating the NPV was 11 years and a 7% discount rate was 
applied as before.
Return on investment
To calculate the ROI from malaria investments, the 
NPV of the benefits of reduced transmission were sub-
tracted from the discounted cost of elimination. The 
resulting figure was divided by the discounted cost of the 
fully funded response (compared to baseline). The ROI 
is interpreted as the economic return from every addi-
tional dollar spent on malaria above the business as usual 
scenario.
Financial gap
Various sources were consulted to estimate past, present, 
and future financing for malaria. Projected financing was 
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estimated using projected figures from GOG, the Global 
Fund and PMI. Many of malaria services are covered 
under the NHIS via the health insurance levy. These esti-
mated resources are included in under “domestic financ-
ing” (obtained from the NMCP).
Sensitivity analysis
A stochastic sensitivity analysis on the epidemiologi-
cal and cost outputs of the malaria transmission model 
was performed. The minimum, median, and maximum 
malaria cases and deaths predicted by the model for each 
scenario were used to calculate the minimum, median, 
and maximum costs. Three hundred random samples 
were drawn, which generated a range of costs. From 
the range of costs generated, the minimum, maximum, 
median, mean, and other percentiles are presented.
Data collection, tools and analysis
A worksheet was developed in Microsoft  Excel® to facili-
tate the organization of cost data. Analysis of the cost 
data was conducted in Microsoft Excel to estimate the 
current and future costs of the malaria activities in each 
scenario. All quantitative data records (no identifying 
information), were stored in Microsoft Excel spread-
sheets on encrypted, password-protected computers. 
Data was collected in August 2019.
Ethical approval
Ethical approval for this study was obtained from the 
Ethical Review Committee (ERC) of the Ghana Health 
Service prior to data collection (GHS/RDD/ERC Ref No. 
1913445).
Study limitations
A number of known and unknown factors limit the find-
ings of this report. Due to time and resource constraints, 
the transmission model estimated sub-national malaria 
transmission based on three climatic zones. Ideally, 
higher levels of spatial heterogeneity would be modelled 
to provide to enable subnational estimates of interven-
tions and costs.
The costs of interventions have been estimated based 
on available data from the NMCP and proxies when data 
were unavailable. For example, the costs of outpatients, 
in-patients and health worker salaries were estimated 
from the National Health Accounts (NHA). Separat-
ing out the cost of interventions in integrated systems is 
challenging and the analysts have relied on country-level 
partners to arrive at disaggregated costs. This report uti-
lized reported cases from the HMIS and estimated cases 
and deaths from WHO World Malaria Reports. The 
wide variation in these two estimates of burden makes it 
harder to be sure of the resources required to eliminate 
the disease.
As Ghana progressively moves from a high to a low 
burden country the impact of active surveillance on both 
the epidemiology and cost will need to be incorporated. 
This was not included due to a lack of historical data 
to enable fitting the model for impact or cost. The sav-
ings observed may well be offset by the increased costs 
of active surveillance required in elimination settings. 
At the same time, targeting of interventions rather than 
ubiquitous coverage to the entire country may reduce 
the costs of elimination and the financing gap. Without 
subnational estimates of incidence and coverage, targeted 
interventions are difficult to estimate and cost. Without 
an informed and complete understanding of the detailed 
current cartography of malaria risk and prevalence, 
future projections of the cost of eliminating malaria face 
an overwhelming uncertainty.
While employee absenteeism was included in the 
estimates of benefits, the analysis did not include the 
economic benefits conferred by reductions in school 
absenteeism and subsequent improvements in cogni-
tive development due to the lack of empirical evidence 
to enable converting these estimates to wages earned. 
Other benefits not included were the potential benefits 
on tourism, the impact of economic development and 
housing improvements on malaria transmission as well 
as regional or cross border externalities.
Results
Epidemiological impact of partial vs full funding 
(transmission model predictions and projections)
Baseline response
Maintaining the interventions (LLIN distribution, IRS, 
SMC) and health system access and performance at 
2018 levels, does not change the transmission intensity. 
Figure  1 shows that malaria is predicted to continue 
unabated, with no further decrease expected until 2030 
(the end point of the model). The slight upward trend in 
cases is a reflection of a growing population, rather than 
increased incidence of malaria. The lower line represents 
the reported cases using WHO estimates while the upper 
line represents the estimated clinical cases based on cor-
rections for reporting rate in the public sector. The true 
number is likely to be somewhere in between.
Fully‑funded/NSP response
Transmission levels decrease starting in 2020 when the 
interventions begin. The total number of reported cases 
however does not fall below 3.5 million annually during 
the 10-year period (2020–2029), as illustrated in Fig.  2. 
Compared to the baseline, the fully funded NSP scenario 
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will avert 37.4 million clinical cases, 21.2 million reported 
cases and 2683 deaths.
Better net use
Figure 3 shows that the impact of improved usage results 
in a considerable predicted decrease in malaria cases at 
the national level with reported cases falling below 1 mil-
lion in 2029, however transmission did not fall to elimi-
nation levels. These predictions assume that improved 
usage will be maintained consistently until 2030.
It must be noted that studies have shown that LLIN use 
varies considerably by urbanization and socio-economic 
status with low net use being recorded among higher 
income households in urban areas [25]. Given that the 
only data available were national averages, it is likely that 
the impact of net use is overestimated if indeed, use is 
high amongst the population at risk in rural areas but low 
amongst those living in low-risk urban areas.
Health system acceleration
Figure  4 shows the impact of combining better net 
use with an increase in access to the public health 
system through SBC and IEC interventions. Mod-
elling this improvement in access as an increase in 
Fig. 1 Baseline scenario (business as usual)
Fig. 2 Fully-funded scenario (predicted impact of interventions as outlined in the NSP)
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treatment-seeking behaviour from 73% (reported) to 
90%, results in a model prediction of reaching malaria 
elimination. Compared to the baseline, the HSA sce-
nario will avert 85.6. million clinical cases, 51.3 million 
reported cases and 4468 deaths, bringing transmission 
down significantly to near elimination by 2026.
Reverse scenario 1
Removing IRS, SMC and reducing LLIN coverage by 50% 
will result in an almost immediate upsurge of cases. By 
2028, reported cases increase to more than 10.6 million 
(Fig. 5).
Reverse scenario 2
Removing IRS and SMC similarly reverse the gains made 
with reported cases rising to over 8.5 million by 2029 and 
clinical cases to 13.5 million (Fig. 6).
Zonal differences
Figure  7 illustrates the zonal differences of interven-
tion impact. Better net use and the fully funded sce-
nario have less of an impact on transmission in the forest 
zone compared to the other two zones. Indeed, it would 
appear that this zone, having the largest case load, has the 
Fig. 3 Better net use scenario (predicted impact of interventions as outlined in the NSP plus better use of nets at the household level)
Fig. 4 Health system acceleration scenario (predicted impact of interventions as outlined in the NSP plus better use of nets at the household level 
plus health system strengthening for improved health-seeking behaviours and more effective case management of malaria)
Page 9 of 15Shretta et al. Malar J          (2020) 19:196  
greatest impact on the total national response and hence 
experiences the greatest impact from the HSA scenario.
Figure 8 summarizes the total clinical cases and deaths 
(2020–2029) with the baseline, HSA and reverse scenar-
ios. Over the course of 10 years, the baseline scenario will 
result in 105 million clinical cases and 5122 deaths. The 
accelerated health system scenario will result in 19 mil-
lion cases and 676 deaths while the reverse I scenario will 
result in 143 million cases and 7642 deaths.
Cost projections
The cost of implementing the HSA scenario is depicted 
in Fig. 9. The model predicted that it will cost a total of 
USD 961.3 million over 10 years (2020–2029) to imple-
ment the HSA scenario (to reach elimination). This 
equates to about USD 133 million annually for the first 
5 years, assuming that the aggressive interventions pre-
dicted by the model are implemented in the most effi-
cient way. This includes the integrated health system 
cost of treating outpatients and inpatients. The cost for 
the HSA scenario in 2020, not taking integrated costs 
into account, is USD 41.6 million. The peaks represent 
LLIN procurement for national mass campaigns which 
occur every 3 years in Ghana. To account for potential 
underestimation of reported cases, both reported and 
estimated cases were used to calculate modelled costs 
and benefits.
Fig. 5 Reverse scenario 1 (predicted impact of removing IRS, SMC and reducing LLIN coverage by 50%)
Fig. 6 Reverse scenario 2 (predicted impact of removing IRS and SMC)
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Benefits estimation
The HSA scenario will avert 85.6 million clinical cases, 
51.3 million reported cases and 4468 deaths. Economic 
benefits of USD 31.73 billion (NPV) are generated 
through reductions in deaths, cases, and household and 
healthcare system spending as well as increases in pro-
ductivity at a cost of USD 961.34 million (2020–2029).
Reducing funding for IRS and SMC will incur addi-
tional (to the current baseline scenario) economic losses 
of USD 4.4 billion in addition to an additional 13 million 
clinical cases, 8.9 million reported cases and 1350 deaths. 
Further reducing funding for LLINs by 50% as well will 
incur economic losses 14.1 billion in addition to an addi-
tional 38.2 million clinical cases, 24.4 million reported 
cases and 2497 deaths. A summary of the results of vari-
ous scenarios is shown in Table 3.
Return on investment
Implementing the HSA scenario which will allow the 
country to progress to elimination and will produce a 
return on investment of 32:1 between 2020 and 2029 
(Table 3).
Fig. 7 Predicted P. falciparum cases by zone for all modelled scenarios. Predictions of impact of interventions vary by zone (Upper line = clinical 
cases; Lower line = reported cases)
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Gaps in malaria financing
The expected influx of financing (both domestic and 
donor) was compared with the projected cost of the 
malaria programme from 2020 to 2021. The modelled 
cost of the elimination scenario was estimated at 961.3 
million (2020–2029). This equates to about USD 133 
million annually for the first 5 years, assuming that the 
aggressive interventions predicted by the model are 
implemented in the most efficient way. This includes 
the integrated health system cost of treating outpa-
tients and inpatients.
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Fig. 9 Cost projections for the HSA (elimination) scenario 2018–2030 (median, ± 25%). Elimination is predicted to cost a total of USD 961.3 million 
over 10 years (2020–2029) with the HSA scenario
Table 3 Median costs and benefits of the baseline response against malaria compared to counterfactuals, 2020–2030
Scenario comparisons (Baseline—
Intervention)
Clinical cases averted Reported 
cases averted
Deaths averted Economic benefits 
(NPV USD)
Cost (USD) (discounted)
Fully funded NSP scenario vs baseline 37,434,462 21,221,433 2683 14.1 billion 1.31 billion
Elimination scenario (HSA) vs baseline 85,571,086 51,251,099 4468 31.7 billion 961.3 million
Additional clinical 
cases
Additional 
reported 
cases
Additional 
deaths
Additional 
economic losses 
(NPV USD)
Baseline vs reverse I 38,220,597 24,411,310 2497 14.1 billion
Baseline vs reverse II 12,974,304 8,914,008 1350 4.4 billion
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In addition to domestic government financing, Ghana 
received about USD 44 million from the Global Fund in 
2018 and an USD 29 million from other donors [5]. In 
order to scale up the interventions needed, the remaining 
USD 60 million annually will need to be met by domes-
tically. It is important to note that these figures do not 
account for the increased levels of co-financing levels 
that may be required by the Global Fund.
Discussion
The current NSP was developed as a “malaria control” 
strategy rather than an “elimination” strategy. Therefore, 
as expected, implementing the interventions outlined 
therein will improve malaria control in Ghana and lower 
mortality and morbidity, but will not significantly lower 
transmission rates to levels that allow the programme 
to embark on malaria elimination. Elimination will only 
be achieved through the increased use of nets, improved 
health-seeking behaviour and strengthened malaria case 
management at the facility level as modelled in the HSA 
scenario.
The findings also indicate that the effects of the inter-
ventions vary by epidemiology and geographical zone. In 
the Forest Zone, which has the highest number of cases, 
better case management and increased treatment-seek-
ing has the biggest impact in lowering transmission. In 
contrast, the Coastal and Savanna Zones the fully funded 
scenario and better net use and have more of an impact. 
The Savanna Zone has the lowest number of total cases 
and the fully funded scenario (NSP interventions) pre-
dicted a reduction in transmission significantly. These 
findings indicate that as transmission declines, there is a 
need to better stratify the risk of transmission in the vari-
ous areas and target interventions purposefully to make 
an impact.
This analysis found that the cost of implement-
ing the most effective scenario was USD 961.3 million 
over 10 years (2020–2029) equating to about USD 133 
million annually for the first 5  years, assuming inter-
ventions are implemented efficiently. The health and 
economic benefits are enormous. Reducing transmis-
sion to elimination levels will avert 85.6 million clini-
cal cases, 51.3 million reported cases and 4468 deaths. 
Economic benefits of USD 31.73 billion are generated 
through reductions in deaths, cases, and household 
and healthcare system spending as well as increases in 
productivity. The economic return is significant at 32 
times the investment. This by far exceeds the thresh-
old on returns that are considered to be high impact 
investments. In contrast, reducing funding for IRS and 
SMC will incur additional economic losses of USD 4.4 
billion, an excess of 13 million clinical cases, 8.9 mil-
lion reported cases and 1350 deaths. Further reducing 
funding for LLINs by 50% will incur economic losses 
USD 14.1 billion in addition to an excess of 38.2 mil-
lion clinical cases, 24.4 million reported cases and 2497 
deaths.
The benefits of investing in malaria elimination are 
likely to be undervalued as they exclude certain macro-
economic costs that extend far beyond the health system. 
Studies have shown that indirect costs of malaria account 
for a large share of societal costs due to its debilitating 
effect on the economy through employee and school 
absenteeism, cognitive development in children as well 
as macroeconomic development by limiting foreign 
investments and tourism [26–30]. These have not been 
included due to the lack of accurate data to quantify these 
effects and to directly attribute them to malaria. Other 
costs to the health system such as cost of drug and insec-
ticide resistance, the cost of higher price alternatives, the 
cost associated with their implementation, and the cost 
of research and development have also been omitted. 
The total income approach was used to compute income 
losses from malaria mortality. Although this methodol-
ogy provides more generous estimates of economic losses 
than other methods, it is unlikely to account for all the 
aforementioned losses.
There are several limitations to the data and meth-
ods used in this study. Obtaining accurate data on the 
cost of programme operations, particularly in an inte-
grated health system, is challenging. Several malaria pro-
gramme resources are shared across other public health 
programmes, particularly for activities that are financed 
through government funding. Facility staff perform other 
health functions and therefore outpatient and inpatient 
costs are derived from estimates from the NHA.
The scenarios were developed in collaboration with the 
NMCP based on the current knowledge of interventions 
and strategic direction of the programme. As the pro-
gramme progresses and transmission is reduced, these 
interventions are likely to the reviewed and revised.
Despite the robust benefits associated with investing 
in malaria, Ghana’s programme is likely to face a gap in 
funding in the immediate future. Funding for malaria 
from government sources met less than 30% of the total 
needs. Ghana is currently highly dependent on financ-
ing from the Global Fund at USD 36 million per year 
on average [31]. The current Global Fund grant ends in 
2020. A funding request to the Global Fund for malaria 
will be developed for the period of 2021–2023. However, 
given that Ghana is already a lower middle-income coun-
try, as cases decline, it is unlikely that the Global Fund 
will maintain its current levels of funding, particularly 
if the co-financing requirement remains unpaid. These 
financing gaps will need to be met by increased domes-
tic financing. A robust resource mobilization strategy 
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bolstered by the epidemiological and economic evidence 
generated by this report will be needed.
In 2015, a Resource Mobilization Plan for National 
Malaria Control Strategy (2014–2020) [32] was devel-
oped and laid the foundation for resource mobilization 
efforts for malaria in Ghana. The subsequent Ghana 
Health Service Resource Mobilization Strategy for 
National Malaria Control and Elimination (2019–2023) 
[4] is awaiting finalization and ratification. At the same 
time, several actions have since been taken: The Ghana 
Malaria Foundation (GMF), established in 2015/2016 
and officially inaugurated in 2017 has been accredited as 
a limited guarantee corporate body. However, a renewed 
effort incorporating the evidence from this report is 
needed, which includes outlining clear actions for imple-
menting identified strategies for resource mobilization.
Ghana’s private sector is large and growing, and 
its engagement in supporting the implementation of 
malaria control interventions during the past decade has 
increased. Engagement includes corporate social respon-
sibility programmes (e.g., through oil companies), work-
place wellness programmes (e.g., plantations), marketing 
of effective malaria treatment and prevention products 
and services and other public–private partnerships 
including market catalyzation for malaria control prod-
ucts. Several opportunities exist to expand these efforts 
in support of the new strategy.
Remittances are one of the largest sources of funding 
flows next to international aid. Providing a small por-
tion of each transaction to malaria — possibly through a 
Corporate Social Responsibility model via mobile trans-
action companies should be explored, especially since 
these funds could be applied to a matching fund scheme. 
In 2017, remittances made up 5.1% of Ghana’s GDP to 
the tune of USD 2.19 billion and which, according to the 
Bank of Ghana, grew to USD 3.52 billion in 2018 [32].
Public and private sector donors can enter into match-
ing fund programmes, which would substantially increase 
donations for Ghana’s national malaria programming. 
For example, in Mozambique, DFID and the Global Fund 
matched Ecobank Foundation’s USD 750,000 donation 
for an LLIN campaign in the country, raising the value of 
that donation to USD 2.5 million. Ghana could explore 
developing a matching co-financing facility with private 
sector companies, such as those from the extraction 
industry and financial sector, and other donors. Other 
opportunities to create an enabling environment include 
tax incentives from the government for private sector 
involvement.
Engagement with companies to raise funds from cus-
tomers and employees to contribute to the GMF may be 
a viable option. Potential mechanisms are voluntary con-
tributions through online banking platforms or similar 
online systems. For example, the Ecobank Foundation 
invited Ecobank employees on World Malaria Day 2017 
to donate USD 3.00 for an LLIN to be distributed to 
vulnerable populations. With little effort, out of 16,000 
employees, Ecobank raised USD 22,000. This can serve 
as an example for other companies to help fill the NMCP 
gaps [32].
Currently, the Government collects taxes on tobacco 
products, alcohol and soda, tourism and airport levies, 
petroleum revenues, lottery funds and others. However, 
none of these are currently earmarked for health and 
present a potential opportunity for increased resources. 
By law, 0.5% of new funding allocated within the District 
Assembly Common Fund is mandated to be used toward 
malaria control and elimination efforts at the district 
level. These funds are frequently not being used for this 
purpose and advocacy to ring-fence the funds is needed.
Other opportunities include using existing resources 
more efficiently. The current cost of the programme does 
not include measures to improve efficiencies. Targeted 
interventions such as vector control to high risk areas 
and populations will likely provide considerable cost-
efficiencies. The implementation of efficiency measures 
in malaria programming can also serve as an advocacy 
tool to approach existing and new donors. These strate-
gies can be made more effective through the use of key 
influencers or ambassadors to ensure accountability.
Conclusions
The findings indicate that while the interventions out-
lined in the NSP will lower transmission of malaria, they 
are not likely to allow the elimination of the disease. 
Elimination will only be achieved through increased use 
of nets, improved health-seeking behaviour and strength-
ened malaria case management at the facility level. The 
effects of these interventions vary by zone and there is 
a need for risk stratification and to target interventions 
particularly as transmission declines and the coun-
try moves closer to elimination. Furthermore, as cases 
decline and the epidemiology of the disease changes, a 
similar exercise with revised elimination interventions 
will need to be conducted with the additional costs of 
surveillance built in.
Eliminating malaria will avert 85.6 million cases and 
4500 deaths. 1.06 billion days of employee absenteeism 
will be avoided conferring economic benefits of 31.73 
billion providing a return on investment of 32:1. Reduc-
ing investments and a resulting resurgence will lead to 
an additional 38.2 clinical cases, 2500 deaths and addi-
tional economic losses of USD 14.1 billion. There are 
several critical reasons why malaria should receive a spe-
cial focus for financing. Malaria is a major ongoing cost 
driver burdening national health systems and eliminating 
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the disease will confer public health benefits as well as 
major cost savings to national health systems. Although 
the short-term investment needed may seem substan-
tial at USD 961.3 million over 10  years (2020–2029), 
front loading investments will provide cost savings in the 
longer term as well as substantial health and economic 
returns. At the same time, Ghana could be at the fron-
tier of elimination in Africa amongst the identified WHO 
High-Burden High-Impact countries in Africa. There is a 
need for a robust and effective resource mobilization and 
advocacy strategy backed by the evidence produced by 
this body of work.
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